Novartis issued the following dividend and 2024 guidance and updated mid-term guidance. Says dividend of CHF 3.30 per share, an increase of 3.1%, proposed for 2023. 2024 net sales expected to grow mid single digit and core operating income expected to grow high single digit. Updated mid-term guidance sees net sales expected to grow 5% cc CAGR 2023-2028 with core operating income margin expanding to about 40%-plus by 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVS:
- Novartis AG (NVS) Q4 Earnings Cheat Sheet
- Novartis initiated with an Equal Weight at Morgan Stanley
- FDA instructs drugmakers to add T cell malignancy risk info to CAR-T labels
- OPDP says Novartis’ Kisqali TV ad makes false or misleading representations
- Novartis says Lutathera reduced risk of disease progression, death in study